AstraZeneca to present diabetes drug data at EASD 2015

AstraZeneca is attending this week's European Association for the Study of Diabetes (EASD) in Stockholm, where it is sharing its latest diabetes drug research insights.

A total of 54 abstracts from the company's research and development efforts in the diabetes field will be presented at the conference, which began on September 14th and runs until the 18th.

Presentations will include data on a number of approved products for the treatment of type 2 diabetes, including Forxiga, Onglyza, Bydureon and Byetta injection, as well as an investigational combination of saxagliptin and dapagliflozin that is currently being reviewed by regulatory authorities in the US and EU.

Additionally, several abstracts will be presented that highlight AstraZeneca's early-stage and preclinical research exploring novel pathways and modalities to address the underlying pathophysiology of diabetes.

Elisabeth Bjork, vice-president and head of cardiovascular and metabolic diseases for global medicines development at AstraZeneca, said: "The breadth and depth of research we're presenting at EASD demonstrates our continuous commitment to developing innovative diabetes treatments."